FALCON
Dead · Refused DEAD/APPLICATION/Refused/Dismissed or Invalidated
What this record means
The record shows that the “FALCON” application filed by Novartis AG (an Aktiengesellschaft organized in Switzerland) is dead – it was abandoned on June 25 2026 after the applicant failed to respond to an Office action, and the mark never entered the register. The filing covered only Class 005 pharmaceuticals, listing anti‑infectives, anti‑inflammatories, antibiotics, antivirals, cardiovascular and dermatological medicines, inhaled preparations for respiratory disease, central‑nervous‑system drugs and a host of other therapeutic categories. Because the claim is limited to those pharmaceutical goods, a similar name used for anything outside that scope would present the closest record‑based concern in the drug and medical‑product arena, but the record does not give Novartis control over every possible use of the word “FALCON.” The prosecution history shows the usual sequence of examiner assignment, a non‑final action in March 2026 and the abandonment notice in June 2026, with no oppositions, cancellations or court actions noted. I'd treat this as a meaningful concern if you plan a pharma‑related brand, but the risk drops sharply for unrelated goods or services.
Informational only - not legal advice.Mark Trademark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Intent-to-Use (§1(b)). |
| Status | Abandoned because the applicant failed to respond or filed a late response to an Office action. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page. |
Key dates
| Application filed | Jan 26, 2026 |
| Status date | Jun 25, 2026 |
Goods & services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Owner & representation
| Owner | Novartis AG |
| Address | CH-4002, Basel SWITZERLAND 4002 |
| Entity | AKTIENGESELLSCHAFT (AG) - organized in SWITZERLAND |
| Attorney of record | Maury M. Tepper, III |
| Correspondent | Maury M. Tepper, III |
| Attorney email | m********@*****.com |
| Correspondent email | 2 emails |
| Correspondent phone | 1********3 |
| Correspondent address | Raleigh, NORTH |